We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
-23.86%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$3.2B
AUM Growth
-$1.2B
Cap. Flow
+$5.31M
Cap. Flow %
0.17%
Top 10 Hldgs %
52.42%
Holding
74
New
3
Increased
14
Reduced
34
Closed
4

Top Buys

Rank Stock Value
1
ONEM
1Life Healthcare
ONEM
+$38.1M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$31.7M
3
CNC icon
Centene
CNC
+$23.6M
4
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$18.2M
5
RAPT
RAPT Therapeutics
RAPT
+$17.7M

Top Sells

Rank Stock Value
1
ICUI icon
ICU Medical
ICUI
+$27.6M
2
GMAB icon
Genmab
GMAB
+$26.2M
3
UNH icon
UnitedHealth
UNH
+$24.6M
4
ZGNX
Zogenix, Inc.
ZGNX
+$16.2M
5
ELV icon
Elevance Health
ELV
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Consumer Staples 2.8%
3 Industrials 1.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONEM
26
DELISTED
1Life Healthcare
ONEM
$37.7M 1.18%
+3,404,835
New +$38.1M
OSH
27
DELISTED
Oak Street Health, Inc.
OSH
$32.4M 1.01%
1,203,619
– –
TNDM icon
28
Tandem Diabetes Care
TNDM
$1.17B
$31.5M 0.98%
+271,218
New +$31.7M
SLGC
29
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$31.3M 0.98%
3,906,770
-236,000
-6% -$2.08M
SRRK icon
30
Scholar Rock
SRRK
$5.71B
$31M 0.97%
2,407,326
-40,600
-2% -$694K
NVTA
31
DELISTED
Invitae Corporation
NVTA
$30.3M 0.95%
3,805,403
– –
NVRO
32
DELISTED
NEVRO CORP.
NVRO
$29.7M 0.93%
411,017
+140,901
+52% +$10.2M
GRTS
33
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$28.3M 0.88%
6,871,738
+3,442,567
+100% +$18.2M
UNH icon
34
UnitedHealth
UNH
$382B
$27.3M 0.85%
53,445
-51,043
-49% -$24.6M
PRTA icon
35
Prothena Corp
PRTA
$458M
$26.9M 0.84%
736,175
-29,500
-4% -$1.06M
ISEE
36
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$25M 0.78%
1,485,800
-14,200
-0.9% -$210K
STTK icon
37
Shattuck Labs
STTK
$710M
$23.9M 0.75%
5,619,914
– –
STVN icon
38
Stevanato
STVN
$5.37B
$23.1M 0.72%
1,150,225
-20,000
-2% -$349K
AKRO
39
DELISTED
Akero Therapeutics
AKRO
$22.7M 0.71%
1,602,285
– –
PLRX icon
40
Pliant Therapeutics
PLRX
$67.5M
$21.6M 0.67%
3,080,801
-2,700
-0.1% -$27.6K
ICUI icon
41
ICU Medical
ICUI
$3.93B
$21.6M 0.67%
96,869
-123,057
-56% -$27.6M
TRDA icon
42
Entrada Therapeutics
TRDA
$227M
$18.4M 0.57%
1,954,419
-1
-0% -$11
BVS icon
43
Bioventus
BVS
$799M
$18.3M 0.57%
1,296,739
-28,400
-2% -$380K
NUVB icon
44
Nuvation Bio
NUVB
$2.24B
$18.3M 0.57%
3,471,709
-199,300
-5% -$1.12M
JAZZ icon
45
Jazz Pharmaceuticals
JAZZ
$15.9B
$17.9M 0.56%
114,764
+16,700
+17% +$2.42M
TOI icon
46
The Oncology Institute
TOI
$498M
$17.2M 0.54%
2,414,432
-85,568
-3% -$577K
RAPT
47
DELISTED
RAPT Therapeutics
RAPT
$16.5M 0.51%
+93,585
New +$17.7M
ALLK
48
DELISTED
Allakos
ALLK
$14.6M 0.46%
2,559,975
+482,100
+23% +$3.12M
ZYME icon
49
Zymeworks
ZYME
$1.68B
$13.8M 0.43%
2,114,197
+1,239,800
+142% +$11M
ALXO icon
50
ALX Oncology
ALXO
$273M
$13.1M 0.41%
772,397
-9,700
-1% -$166K
1
2
3

Similar funds

KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Redmile Group's Q1 2022 Portfolio in Review

As of Q1 2022, Redmile Group held 74 positions worth $3.2B, down 27% from $4.4B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Redmile Group's Q1 2022 filing shows 3 new, 14 increased, 34 reduced and 4 closed positions. Its largest new stake was 1Life Healthcare: 3,404,835 shares worth $37.7M. The largest sale was ICU Medical, an estimated $27.6M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Industrials.

  • Redmile Group's largest Q1 2022 buy was 1Life Healthcare: 3,404,835 shares worth $37.7M.
  • Redmile Group added most to Centene in Q1 2022, an estimated $23.6M increase.
  • Redmile Group's biggest Q1 2022 reduction was ICU Medical, cutting an estimated $27.6M.
  • Redmile Group fully exited Genmab in Q1 2022, selling an estimated $26.2M.
  • Redmile Group's ten largest holdings make up 52% of its $3.2B portfolio in Q1 2022.
  • Redmile Group opened 3 new positions and closed 4 in Q1 2022.
  • Redmile Group's portfolio value fell 27% quarter-over-quarter to $3.2B.

Based on Redmile Group's 13F filing for Q1 2022, filed 16 May 2022.